Global Allogeneic Cell Therapy Market Size is valued at 997.36 Million in 2022 and is predicted to reach 2853.34 Million by the year 2031 at a 12.7 % CAGR during the forecast period for 2023 to 2031.
Allogeneic Cell Therapy Market Size, Share & Trends Analysis Report By Type of Cell Therapy (Virus-Specific T-Cell, Stem Cell, Regulatory T-Cell), By Source of Cell, By Target Indication, By Therapeutic Area, Region And Segment Forecasts, 2023 to 2031

Key Industry Insights & Findings from the Report:
Global Allogeneic cell therapies use the transfer of cells from a donor to a patient. Stem cells collected from the donor whose tissue type closely matches that of the patient are predominantly utilized in allogeneic cell therapies. There are various sources to get allogeneic cells, among which blood is taken from the placenta, and the umbilical cord of newborns is the prominent source of cells for allogeneic transplants. The small volume of blood comprises a high number of cells that are eligible to multiply quickly.
Moreover, raising prevalence of chronic diseases and increasing funding for stem cell research start-ups are driving the growth of allogeneic stem cell therapy market. Currently, many companies are developing a wide range of tissue-engineered products and allogeneic cell therapies aiming to bring about an era of regenerative medicine to treat people with unmet medical needs. Additionally, a rise in the prevalence of cancer and cardiovascular diseases is expected to boost the global allogeneic stem cell therapy market. For instance, JKastrup has an ongoing Phase II clinical trial for allogeneic adipose tissue-derived stromal/stem cell therapy in patients with ischemic heart disease and heart failure.
Global Allogeneic cell therapies market is segmented on the basis of cell type, cell/tissue source, indication, and region. Based on the cell type, the market is divided into Cardiosphere-derived cells (CDCS), fibroblasts, t-cells, mesenchymal stem cells (MSCS), hematopoietic stem cells (HSCS) and others. Based on cell/tissue source, the market is segmented into skin, blood, PBC, BM and others. Based on the indication, the market is divided into acute graft-versus-host disease (gvhd), chronic ulcers and diabetic foot ulcers, osteoarthritis, crohn’s disease, cardiovascular disease, solid tumors/cancers and others (alzheimer’s disease, etc). Based on region, the maarket is studied across North America, Asia-Pacific, Europe, and LAMEA. Among that Europe held the largest share of the market, followed by America and Asia Pacific. On the other hand, North America is expected to dominate the market during the analysis of the forecast period.
| Report Attribute | Specifications |
| Market Size Value In 2022 | USD 997.36 Million |
| Revenue Forecast In 2031 | USD 2853.34 Million |
| Growth Rate CAGR | CAGR of 12.7 % from 2023 to 2031 |
| Quantitative Units | Representation of revenue in US$ Million and CAGR from 2023 to 2031 |
| Historic Year | 2019 to 2022 |
| Forecast Year | 2023-2031 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Type of Cell Therapy, By Source of Cell, By Target Indication, By Therapeutic Area |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
| Competitive Landscape | Juno Therapeutics, Agios Pharmaceutical, Aurora BioPharma, Atara Biotherapeutics, AryoGen Biopharma, Shenzhen BinDeBio Ltd., China Immunotech Co., Ltd., Autolus Limited, Kite Pharma, Bellicum Pharmaceuticals, bluebird bio,Calibr, Carina Biotech, CARsgen Therapeutics, Celgene Corporation, Cellectis, Cell Medica, AbbVie, Allogene Therapeutics, Amgen, Cell Design Labs, Celularity, Celyad, Fate Therapeutics, Fortress Bio, Gilead Sciences, Sorrento Therapeutics, Inc., Ziopharm,Janssen Biotech, JW Therapeutics, Medisix Therapeutics, Mustang Bio, Nanjing Legend Biotech, Precision Biosciences, and Posedia Therapeutics, and Others |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing and Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Allogeneic Cell Therapies Market Revenue (US$ Mn) by Type of Cell Therapy

Allogeneic Cell Therapies Market Revenue (US$ Mn) Based on Source of Cell
Allogeneic Cell Therapies Market Revenue (US$ Mn) Based on Target Indication
Allogeneic Cell Therapies Market Revenue (US$ Mn) Based on Therapeutic Area
Allogeneic Cell Therapies Market Revenue (US$ Mn) Based on Region
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.